Reduction of Nocturnal Awakenings With Mometasone Furoate Administered Via Dry Powder Inhaler in Children With Persistent Asthma Previously Receiving Other Inhaled Corticosteroids

2011 ◽  
Vol 127 (2) ◽  
pp. AB159-AB159
Author(s):  
W.E. Berger ◽  
M. Noonan ◽  
A. Teper ◽  
J. Moreno-Cantu ◽  
P. Stryszak ◽  
...  
Keyword(s):  
Inhaled Corticosteroids ◽  
Dry Powder Inhaler ◽  
Persistent Asthma ◽  
Mometasone Furoate ◽  
Dry Powder

Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma

2006 ◽  
Vol 97 (5) ◽  
pp. 672-680 ◽  
Author(s):  
William E. Berger ◽  
Henry Milgrom ◽  
Paul Chervinsky ◽  
Michael Noonan ◽  
Steven F. Weinstein ◽  
...  
Keyword(s):  
Dry Powder Inhaler ◽  
Persistent Asthma ◽  
Mometasone Furoate ◽  
Dry Powder

scholarly journals Mometasone furoate dry powder inhaler for the treatment of asthma

2012 ◽  
Vol 9 (4) ◽  
pp. 79-87
Author(s):  
A V Emelyanov ◽  
L A Goryachkina
Keyword(s):  
Antiinflammatory Activity ◽  
Dry Powder Inhaler ◽  
Persistent Asthma ◽  
Mometasone Furoate ◽  
Inhaled Corticosteroid ◽  
Dry Powder ◽  
Safety And Efficacy ◽  
Therapeutic Choice ◽  
Efficacy Profile

The review is focused on inhaled mometasone furoate (Asmanex Twisthaler), a new medication for the treatment of asthma in adults and childred (12 years and older). Mometasone furoate (MF) has high antiinflammatory activity and low systemic bioavalability. MF has an excellent safety and efficacy profile in approved doses 200—800 mcg/daily od (in the evening) or bid (in the morning and in the evening). For patients with persistent asthma required treatment with an inhaled corticosteroid, MF is an excellent therapeutic choice.

Sign in / Sign up

Export Citation Format

Share Document